%0 Journal Article %1 sliao2021glycopolypeptides %A S Liao, Benedict %A Harvowitz, Elizabeth %A Liao, Austin %A Liao, Alex %A Liao, Burton %A F-C Li, Judy %D 2021 %J Journal of Oncology Research and Therapy (ISSN: 2574-710X) %K Glyco-Polypeptides SolidCarcinoma WhiteBloodCellTherapy %P 10 %R 10.29011/2574-710X.010115 %T Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases %U https://www.gavinpublishers.com/article/view/glyco-polypeptides-and-chimeric-white-blood-cell-therapy-in-late-stage-refractory-solid-carcinoma-of-lung-prostatic-and-bladder-cancers-review-of-35-cases %V 5 %X We employed Glyco-polypeptides in human subjects to induce leucocyte immune production which including interleukins and Tumor Necrotizing Factors (TNF) result in necrosis, fibrinolysis, anti-metastatic effects in late-stage carcinoma of lung, prostate, and bladder, and achieved excellent anti-tumor effects. Then investigation were carried out in animal. The cancer cells cultures were performed in our laboratory. By injection of cancer cell fluid into peritoneal cavity of animal in 6 groups (white rabbits). Tumor growth in animals were obtained in 3 months, then polypeptides were injected into peritoneal cavity every 2 weeks at a dose of 15 mg for 6 months, then animals were sacrificed and examined shown no tumor growth in the peritoneum. We applied FDA phase 2 clinical trials with IND 116911. Tests were carried out in 2 groups, the low dose group on 10 mg/kg/ day, and high dose group on 50 mg/kg/day for a period of more than 6-8 months. A total number of 35 patients with 3rd and 4th stage of refractory solid tumors of lung, prostate, and bladder were enrolled from referring center, 24 patients were not eligible and excluded, whom at least previously failed on two regimens of chemotherapy and /or failed on radiation therapy, the rates of complete response and partial responses in high dose cohort were astonishing with rate of 74% and 20% respectively. Stable diseases and Progressive diseases in high dose cohort were astonishing with rate of 0% and 5.7%. The implications and results of the findings are discussed. P value ≤0.05. Our findings in this study were correspondence with Dr. Maurer, Dr. Eckert, Dr. Harrach and many other authors. Glyco-polypeptides in treating various type of cancers only high dose are effective. There were no hematological, hepato-renal toxicities.

@article{sliao2021glycopolypeptides, abstract = {We employed Glyco-polypeptides in human subjects to induce leucocyte immune production which including interleukins and Tumor Necrotizing Factors (TNF) result in necrosis, fibrinolysis, anti-metastatic effects in late-stage carcinoma of lung, prostate, and bladder, and achieved excellent anti-tumor effects. Then investigation were carried out in animal. The cancer cells cultures were performed in our laboratory. By injection of cancer cell fluid into peritoneal cavity of animal in 6 groups (white rabbits). Tumor growth in animals were obtained in 3 months, then polypeptides were injected into peritoneal cavity every 2 weeks at a dose of 15 mg for 6 months, then animals were sacrificed and examined shown no tumor growth in the peritoneum. We applied FDA phase 2 clinical trials with IND 116911. Tests were carried out in 2 groups, the low dose group on 10 mg/kg/ day, and high dose group on 50 mg/kg/day for a period of more than 6-8 months. A total number of 35 patients with 3rd and 4th stage of refractory solid tumors of lung, prostate, and bladder were enrolled from referring center, 24 patients were not eligible and excluded, whom at least previously failed on two regimens of chemotherapy and /or failed on radiation therapy, the rates of complete response and partial responses in high dose cohort were astonishing with rate of 74% and 20% respectively. Stable diseases and Progressive diseases in high dose cohort were astonishing with rate of 0% and 5.7%. The implications and results of the findings are discussed. P value ≤0.05. Our findings in this study were correspondence with Dr. Maurer, Dr. Eckert, Dr. Harrach and many other authors. Glyco-polypeptides in treating various type of cancers only high dose are effective. There were no hematological, hepato-renal toxicities.}, added-at = {2021-11-24T12:16:56.000+0100}, author = {S Liao, Benedict and Harvowitz, Elizabeth and Liao, Austin and Liao, Alex and Liao, Burton and F-C Li, Judy}, biburl = {https://www.bibsonomy.org/bibtex/2f4d76da771488476307f6ece6fee41ae/alyssacarter}, doi = {10.29011/2574-710X.010115}, interhash = {3398320306e80d81cc5df1ba061ceba1}, intrahash = {f4d76da771488476307f6ece6fee41ae}, issn = {2574-710X}, journal = {Journal of Oncology Research and Therapy (ISSN: 2574-710X)}, keywords = {Glyco-Polypeptides SolidCarcinoma WhiteBloodCellTherapy}, language = {ENGLISH}, month = {October}, pages = 10, timestamp = {2021-11-24T12:16:56.000+0100}, title = {Glyco-Polypeptides (Comosain) and Chimeric White Blood Cell Therapy in Late-Stage Refractory Solid Carcinoma of Lung, Prostatic and Bladder Cancers Review of 35 Cases}, url = {https://www.gavinpublishers.com/article/view/glyco-polypeptides-and-chimeric-white-blood-cell-therapy-in-late-stage-refractory-solid-carcinoma-of-lung-prostatic-and-bladder-cancers-review-of-35-cases}, volume = 5, year = 2021 }